

B7-H2/ICOSLG Protein, Human (HEK293, Fc)

Cat. No.:	HY-P7324
Synonyms:	rHuB7-H2/ICOSLG, Fc Chimera; B7 homolog 2; B7RP-1; CD275
Species:	Human
Source:	HEK293
Accession:	O75144-1 (D19-S258)
Gene ID:	23308
Molecular Weight:	70-80 kDa

PROPERTIES

AA Sequence	<p>DTQEKEVRAM VGS DVELSCA CPEGSRFDLN DVYVYWQTSE</p> <p>SKTVVTYHIP QNSSLENVDS RYRNRALMSP AGMLRGDFS L</p> <p>RLFNVT PQDE QKFHCLVLSQ SLGFQEVLSV EVTLHVAANF</p> <p>SVPVVSAPHS PSQDELTF TC TSINGYPRPN VYWINKTDNS</p> <p>LLDQALQNDT VFLNMRGLYD VVS VLR IART PSVNI GCCIE</p> <p>NVLLQQLTV GSQTGNDIGE RDKITENPVS TGEKNAATWS</p>
Biological Activity	5 µg/mL (100 µL/well) of immobilized recombinant human B7-H2/ICOSLG-Fc can bind human Biotin-B7-H2/ICOSLG-Fc with a linear range of 0.76-12.21 µg/mL.
Appearance	Lyophilized powder.
Formulation	Lyophilized after extensive dialysis against PBS, 5% trehalose and mannitol.
Endotoxin Level	<0.2 EU/µg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH ₂ O.
Storage & Stability	Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	As a member of the B7 family, inducible co-stimulator ligand (ICOSLG) expressed on tumor cell has been reported to have an important role in tumor immunity. As the counter ligand of ICOS, a CD28-related molecule, ICOSLG is expressed on professional antigen-presenting cell (APCs; such as dendritic cells (DCs) and B cells) and on some tumor cells (such as glioma cells and gastric carcinoma cells). ICOSLG is the only B7 family member that preferentially co-stimulates type 2T
-------------------	--

helper cell (Th2) responses, and interestingly, this unique molecule has a critical role in antitumor immunity. ICOSLG expression on solid tumors (implanted-transfected tumors) aids in both NK mediated and CD8⁺ cytotoxic T cell (CTL) activation and killing. Several studies using ICOSLG-transfected solid tumor cell lines found that ICOSLG induced CD8⁺ cytotoxic lymphocyte-mediated tumor regression^[1].

REFERENCES

[1]. Wang B, et al. Effects of ICOSLG expressed in mouse hematological neoplasm cell lines in the GVL reaction. Bone Marrow Transplant. 2013 Jan;48(1):124-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA